JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB52587

Anti-PD1 抗体 [NAT105]

Anti-PD1 antibody [NAT105]

5

(9 Reviews)

|

(328 Publications)

Anti-PD1 antibody [NAT105] (ab52587) is a mouse monoclonal antibody detecting PD1 in Western Blot, Flow Cytometry, IHC-P, IHC-Fr, ICC/IF. Suitable for Human.

- Over 280 publications
- Trusted since 2007

查看别名

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

7 Images
Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)
  • IHC-Fr

Supplier Data

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

Immunohistochemical analysis of permeabilized frozen Human tonsil tissue labeling PD1 with ab316965 at 1/10000 dilution, followed by LeicaDS9800 (Bond™ PolymerRefine Detection). Counterstained with hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [NAT105] (AB52587)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-PD1 antibody [NAT105] (AB52587)

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized MOLT-4 cells labelling PD1 with ab52587 at 1/100 dilution, followed by Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed (ab150117) at 1/1000 dilution at RT for 45 min. Recombinant Alexa Fluor® 594 Anti-beta Tubulin antibody [EPR16774] (ab206369) was used as a counterstain at 1/50 dilution and was co-incubated with ab52587 overnight at 4° C. Nucleus were visualized using DAPI. Confocal image showing membranous staining in MOLT-4 cells treated with 500 ng/ml Ionomycin and 10 ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, and no staining in MOLT-4 cells.

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)
  • IHC-Fr

Supplier Data

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

Immunohistochemical analysis of permeabilized frozen Human cardiac muslce tissue labeling PD1 with ab316965 at 1/10000 dilution, followed by LeicaDS9800 (Bond™ PolymerRefine Detection). No staining on human cardiac muscle. Counterstained with hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (AB52587)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (AB52587)

Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling PD1 with ab52587 at 1/100 dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Citrate buffer (pH 6.0, Epitope Retrieval Solution

  1. for 20 mins.
Flow Cytometry - Anti-PD1 antibody [NAT105] (AB52587)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-PD1 antibody [NAT105] (AB52587)

Cells were fixed with 100µl 4% PFA for 10 min at RT, then permeabilized with 100µl 90% methanol for 30 min (-20° C) followed by blocking with 10% goat serum for 1h at room temperature. Incubate ab52587 for 30 min at room temperature (RT) and then incubate Goat anti-Mouse IgG (Alexa Fluor® 488, ab150113) for 30 min at room temperature. Positive staining on MOLT-4 treated with 10ng/ml PMA and 500ng/ml Ionomycin for 24h, but weak staining on untreated MOLT-4.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (AB52587)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [NAT105] (AB52587)

Immunohistochemical analysis of paraffin-embedded Human cardiac muscle tissue labeling PD1 with ab52587 at 1/100 dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). No staining on human cardiac muscle. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Citrate buffer (pH 6.0, Epitope Retrieval Solution 1) for 20 mins.

Western blot - Anti-PD1 antibody [NAT105] (AB52587)
  • WB

Supplier Data

Western blot - Anti-PD1 antibody [NAT105] (AB52587)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

All lanes:

Western blot - Anti-PD1 antibody [NAT105] (ab52587) at 1/1000 dilution

Lane 1:

Untreated MOLT-4 (human lymphoblastic leukemia T lymphoblast) whole cell lysate at 20 µg

Lane 2:

MOLT-4 treated with 500ng/ml Ionomycin and 10ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, whole cell lysate at 20 µg

false

不同偶联物与剂型 (2)

关键信息

宿主种属

Mouse

克隆

Monoclonal

克隆号

NAT105

亚型

IgG1

轻链类型

kappa

不含载体蛋白

No

反应种属

Human

应用

IHC-P, WB, ICC/IF, Flow Cyt, IHC-Fr

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/1000", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p>We recommend Goat Anti-Mouse IgG H&amp;L (Alexa Fluor<sup>®</sup> 488) (<a href='/products/secondary-antibodies/goat-mouse-igg-h-l-alexa-fluor-488-preadsorbed-ab150117'>ab150117</a>) secondary antibody.</p>", "IHCFr-species-checked": "testedAndGuaranteed", "IHCFr-species-dilution-info": "1/10000", "IHCFr-species-notes": "<p></p>" } } }

产品详情

Anti-PD1 antibody [NAT105] (ab52587) is a mouse recombinant monoclonal antibody and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P and WB.

Anti-PD1 antibody [NAT105] (ab52587) was first used in a scientific publication in 2007 and has been cited over 282 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community.

Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [NAT105] (ab52587) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

Anti-PD1 antibody [NAT105] (ab52587) has 8 independent reviews from customers.

Anti-PD1 antibody [NAT105] (ab52587) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µg) and larger sizes for subsequent scaling up experiments (100 ug and 1 mg).

Conjugation-ready, carrier free format available for antibody clone NAT105 - ab201811.

Antibody clone NAT105 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647, PE, Alexa Fluor® 647, Alexa Fluor® 555 (ab220300, ab220301, ab220302, ab279695, ab280864).

PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Programmed cell death protein 1 commonly known as PD-1 or PDCD1 is an immune checkpoint receptor with a molecular mass of approximately 55 kDa. This protein is primarily expressed on the surface of activated T cells B cells and myeloid cells within the immune system. PD-1 plays a mechanical role in modulating immune responses by binding to its ligands PD-L1 and PD-L2 which are expressed on other immune cells and in various other tissues. The engagement of PD-1 with its ligands transmits an inhibitory signal that reduces the proliferation and activity of T cells.
Biological function summary

PD-1 serves as a critical immune checkpoint that helps maintain self-tolerance and prevent autoimmunity. PD-1 does not function as part of a multi-protein complex but independently regulates the immune response. By delivering inhibitory signals upon ligand binding PD-1 limits the overactivation of the immune system reducing the likelihood of tissue damage during inflammatory responses. The modulation of T cell activity by PD-1 contributes to a balanced immune system ensuring that the body targets pathogens effectively without harming itself.

Pathways

PD-1 interacts with key immune-regulatory pathways including the PI3K-Akt and Ras-MAPK pathways. These pathways are important for cell survival growth and metabolism. The interaction of PD-1 with the PI3K-Akt pathway involves proteins such as SHP-2 which dephosphorylates signaling intermediates leading to reduced T cell receptor signaling. PD-1's role in these pathways demonstrates its influence on immune cell function particularly in regulating the intensity and duration of immune responses.

The PD-1 pathway plays an important role in cancer and autoimmune diseases. Tumors often exploit the PD-1 pathway to evade immune surveillance leading to cancer progression. In such cases blocking PD-1 with inhibitors like anti-PD-1 antibodies (e.g. EH12.2H7 and chimeric antibodies) can re-activate T cells against cancer cells. Conversely in autoimmune diseases heightened PD-1 expression or activity could help in moderating aberrant immune responses where the immune system attacks the body's own tissues. The PD-1 pathway interacting with proteins such as CTLA-4 in cancer and autoimmune contexts represents a target for therapeutics aiming to modulate the immune system to improve disease outcomes.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically.
See full target information PDCD1

文献 (328)

Recent publications for all applications. Explore the full list and refine your search

Journal of translational medicine 23:1056 PubMed41053808

2025

A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.

Applications

Unspecified application

Species

Unspecified reactive species

Liying Song,Sumin Tang,Xuelei Pi,Yuanyuan Yan,Chenxi Hu,Liang Liu,Hongna Chen,Yating Zhang,Shishi Liu,Dan Yu,Chengkai Yin,Tianyan Liu,Xu Li,Deshan Li,Zhenzhong Wang,Wei Zhu,Kaiyuan Hui,Zhihang Liu,Xiaodong Jiang

JCO precision oncology 9:e2500404 PubMed40749151

2025

Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

Applications

Unspecified application

Species

Unspecified reactive species

Denise M Connolly,Gabriel Revon-Rivière,Rose Chami,Denise Mills,Ailish C Coblentz,Thomas S Uldrick,David A Knorr,Priscila Goncalves,Michael Dobosz,Sumreen Jalal,Sarah Cohen-Gogo,Daniel A Morgenstern

Journal for immunotherapy of cancer 13: PubMed40744660

2025

MIAT promotes tumor-infiltrating CD8 T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ming-Xiao Zhang,Lan-Yu Jing,Hao-Tian Tan,Zi-Ran Dai,Da-Zhi Long,Han-Chao Liu,An-Ze Yu,Bin Wang,Zi-Yin Chen,Jun-Hang Luo,Zhen-Hua Chen,Jian-Feng Wang

Cells 14: PubMed40643462

2025

Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Johnny Amer,Ahmad Salhab,Amiram Ariel,Rifaat Safadi

International dental journal 75:100874 PubMed40570672

2025

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions.

Applications

Unspecified application

Species

Unspecified reactive species

Yujin Song,Seohee Park,Hyeseong Jin,Byungyoon Hyun,Kyu-Young Oh

Mediators of inflammation 2025:6217272 PubMed40568348

2025

WTAP Accelerates Exhaustion of CD8 T Cells and Progression of Hepatocellular Carcinoma by Promoting m6A Modification and Translation of PD1 mRNA.

Applications

Unspecified application

Species

Unspecified reactive species

Rong Li,Shunle Li,Hua Li,Bingli Liu,Zimu Wang,Huanqin Lei,Yuting Li,Lijuan Jia,Junhui Li,Hongwei Lu,Meng Xu

Frontiers in immunology 16:1618487 PubMed40568593

2025

Prognostic and immunological implications of cathepsin Z overexpression in prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Junyue Tao,Yiding Chen,Xiaokang Bian,Tingting Cai,Changhao Song,Chaozhao Liang,Zongyao Hao,Jialing Meng,Qintao Ge,Jun Zhou

Cancer genomics & proteomics 22:496-509 PubMed40280722

2025

Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple Metastases.

Applications

Unspecified application

Species

Unspecified reactive species

Shusuke Yoshikawa,Chie Maeda,Akira Iizuka,Tomoatsu Ikeya,Kazue Yamashita,Tadashi Ashizawa,Akari Kanematsu,Haruo Miyata,Yasufumi Kikuchi,Kenichi Urakami,Keiichi Ohshima,Takeshi Nagashima,Ken Yamaguchi,Yoshio Kiyohara,Yasuto Akiyama

European journal of medical research 30:242 PubMed40186294

2025

Development and validation of optimized lentivirus-like particles for gene editing tool delivery with Gag-Only strategy.

Applications

Unspecified application

Species

Unspecified reactive species

Jinlin Jia,Yanzhe Hao,Lu Zhang,Xiaofang Cao,Lisha An,Hu Wang,Qi Ma,Xiaohua Jin,Xu Ma

Journal of biomedical science 32:11 PubMed39838427

2025

The endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 3 attenuates the unfolded protein response and has pro-survival and pro-viral roles in hepatoma cells and hepatocellular carcinoma patients.

Applications

Unspecified application

Species

Unspecified reactive species

Alina-Veronica Ghionescu,Mihaela Uta,Andrei Sorop,Catalin Lazar,Petruta R Flintoaca-Alexandru,Gabriela Chiritoiu,Livia Sima,Stefana-Maria Petrescu,Simona Olimpia Dima,Norica Branza-Nichita
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com